CXCL1 and infection: These findings are consistent with the interpretation that B/F/TAF treatment is not only interacting with EcoHIV infection to alter outcomes, as observed for IL-7 in the NAc or IL-5 in the periphery, but—similar to CXCL1/KC findings within the NAc—is independently altering immune targets, even in the absence of infection.